Genovis AB (Sweden) Performance
| GENO Stock | SEK 27.75 0.30 1.07% |
Genovis AB has a performance score of 2 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of -0.3, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Genovis AB are expected to decrease at a much lower rate. During the bear market, Genovis AB is likely to outperform the market. Genovis AB right now retains a risk of 4.71%. Please check out Genovis AB standard deviation, total risk alpha, treynor ratio, as well as the relationship between the jensen alpha and sortino ratio , to decide if Genovis AB will be following its current trending patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Genovis AB are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Genovis AB may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
| Begin Period Cash Flow | 44.1 M | |
| Total Cashflows From Investing Activities | -4.5 M |
Genovis |
Genovis AB Relative Risk vs. Return Landscape
If you would invest 2,650 in Genovis AB on August 28, 2024 and sell it today you would earn a total of 125.00 from holding Genovis AB or generate 4.72% return on investment over 90 days. Genovis AB is generating 0.1711% of daily returns and assumes 4.706% volatility on return distribution over the 90 days horizon. Simply put, 41% of stocks are less volatile than Genovis, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Genovis AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genovis AB's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Genovis AB, and traders can use it to determine the average amount a Genovis AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0364
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GENO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.71 actual daily | 41 59% of assets are more volatile |
Expected Return
| 0.17 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average Genovis AB is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genovis AB by adding it to a well-diversified portfolio.
Genovis AB Fundamentals Growth
Genovis Stock prices reflect investors' perceptions of the future prospects and financial health of Genovis AB, and Genovis AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genovis Stock performance.
| Return On Equity | 0.37 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.34 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 3.25 B | |||
| Shares Outstanding | 65.47 M | |||
| Price To Earning | 976.19 X | |||
| Price To Book | 25.09 X | |||
| Price To Sales | 26.42 X | |||
| Revenue | 93.02 M | |||
| EBITDA | 30.44 M | |||
| Cash And Equivalents | 81.31 M | |||
| Cash Per Share | 0.17 X | |||
| Total Debt | 1.12 M | |||
| Debt To Equity | 10.60 % | |||
| Book Value Per Share | 2.03 X | |||
| Cash Flow From Operations | 45.92 M | |||
| Earnings Per Share | 0.63 X | |||
| Total Asset | 141.75 M | |||
| Current Asset | 16 M | |||
| Current Liabilities | 16 M | |||
About Genovis AB Performance
Assessing Genovis AB's fundamental ratios provides investors with valuable insights into Genovis AB's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Genovis AB is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Genovis AB develops, produces, and sells tools for developing new medications and diagnostics for customers in the medical device and pharmaceutical industries. Genovis AB was founded in 1999 and is based in Lund, Sweden. Genovis AB operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 20 people.Things to note about Genovis AB performance evaluation
Checking the ongoing alerts about Genovis AB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genovis AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genovis AB had very high historical volatility over the last 90 days | |
| About 24.0% of the company shares are held by company insiders |
- Analyzing Genovis AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genovis AB's stock is overvalued or undervalued compared to its peers.
- Examining Genovis AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genovis AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genovis AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genovis AB's stock. These opinions can provide insight into Genovis AB's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Genovis Stock Analysis
When running Genovis AB's price analysis, check to measure Genovis AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genovis AB is operating at the current time. Most of Genovis AB's value examination focuses on studying past and present price action to predict the probability of Genovis AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genovis AB's price. Additionally, you may evaluate how the addition of Genovis AB to your portfolios can decrease your overall portfolio volatility.